Elevating mitochondrial reactive oxygen species by mitochondria-targeted inhibition of superoxide dismutase with a mesoporous silica nanocarrier for cancer therapy

Nano Research

Volumn 7, Issue 8, 2014, Pages 1103-1115

  Zhang, Yi ^a,b   Hu, Zhengyan ^a,b   Xu, Guiju ^a,b   Gao, Chuanzhou ^c   Wu, Ren’an ^a   Zou, Hanfa ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; drug delivery; mesoporous silica; mitochondria; nanoparticles; reactive oxygen species

Indexed keywords

EID: 84921670389     PISSN: 19980124     EISSN: 19980000     Source Type: Journal    
DOI: 10.1007/s12274-014-0473-4     Document Type: Article

References (39)

1. Sena, L. A.; Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell2012, 48, 158–167.
2. Yang, Y.; Song, Y.; Loscalzo, J. Regulation of the protein disulfide proteome by mitochondria in mammalian cells. Proc. Natl. Acad. Sci. USA2007, 104, 10813–10817.
3. Hamanaka, R. B.; Chandel, N. S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci.2010, 35, 505–513.
4. Simon, H.-U.; Haj-Yehia, A.; Levi-Schaffer, F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis2000, 5, 415–418.
5. Murphy, M. P. How mitochondria produce reactive oxygen species. Biochem. J.2009, 417, 1–13.
6. Wang, J.; Yi, J. Cancer cell killing via ROS: To increase or decrease, that is the question. Cancer Biol. Ther.2008, 7, 1875–1884.
7. Trachootham, D.; Alexandre, J.; Huang, P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat. Rev. Drug Discov.2009, 8, 579–591.
8. Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol.2013, 3, 120144.
9. Qi, Y.; Tian, X.; Liu, J.; Han, Y.; Graham, A. M.; Simon, M. C.; Penninger, J. M.; Carmeliet, P.; Li, S. Bnip3 and AIF cooperate to induce apoptosis and cavitation during epithelial morphogenesis. J. Cell Biol.2012, 198, 103–114.
10. Scherz-Shouval, R.; Shvets, E.; Fass, E.; Shorer, H.; Gil, L.; Elazar, Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J.2007, 26, 1749–1760.
11. Zorov, D. B.; Juhaszova, M.; Sollott, S. J. Mitochondrial ROS-induced ROS release: An update and review. BBA-Bioenergetics.2006, 1757, 509–517.
12. Miwa, S.; Brand, M. D. Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. Biochem. Soc. Trans.2003, 31, 1300–1301.
13. Pelicano, H.; Feng, L.; Zhou, Y.; Carew, J. S.; Hileman, E. O.; Plunkett, W.; Keating, M. J.; Huang, P. Inhibition of mitochondrial respiration: A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem.2003, 278, 37832–37839.
14. Kirshner, J. R.; He, S.; Balasubramanyam, V.; Kepros, J.; Yang, C.-Y.; Zhang, M.; Du, Z.; Barsoum, J.; Bertin, J. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther.2008, 7, 2319–2327.
15. Bragado, P.; Armesilla, A.; Silva, A.; Porras, A. Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation. Apoptosis2007, 12, 1733–1742.
16. Huang, P.; Feng, L.; Oldham, E. A.; Keating, M. J.; Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature2000, 407, 390–395.
17. Zelko, I. N.; Mariani, T. J.; Folz, R. J. Superoxide dismutase multigene family: A comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radical Biol. Med.2002, 33, 337–349.
18. Kamata, H.; Honda, S.-i.; Maeda, S.; Chang, L. F.; Hirata, H.; Karin, M. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell2005, 120, 649–661.
19. Derfus, A. M.; Chan, W. C. W.; Bhatia, S. N. Intracellular delivery of quantum dots for live cell labeling and organelle tracking. Adv. Mater.2004, 16, 961–966.
20. 2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity. Nano Lett.2007, 7, 596–601.
21. Marrache, S.; Dhar, S. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl. Acad. Sci. USA2012, 109, 16288–16293.
22. Wang, L. M.; Liu, Y.; Li, W.; Jiang, X. M.; Ji, Y. L.; Wu, X. C.; Xu, L. G.; Qiu, Y.; Zhao, K.; Wei, T. T. et al. Selective targeting of gold nanorods at the mitochondria of cancer cells: Implications for cancer therapy. Nano Lett.2011, 11, 772–780.
23. Boddapati, S. V.; D’Souza, G. G. M.; Erdogan, S.; Torchilin, V. P.; Weissig, V. Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett.2008, 8, 2559–2563.
24. Farokhzad, O. C.; Langer, R. L. Impact of nanotechnology on drug delivery. ACS Nano2009, 3, 16–20.
25. Cheng, H.; Kastrup, C. J.; Ramanathan, R.; Siegwart, D. J.; Ma, M. L.; Bogatyrev, S. R.; Xu, Q. B.; Whitehead, K. A.; Langer, R.; Anderson, D. G. Nanoparticulate cellular patches for cell-mediated tumoritropic delivery. ACS Nano2010, 4, 625–631.
26. Tarn, D.; Ashley, C. E.; Xue, M.; Carnes, E. C.; Zink, J. I.; Brinker, C. J. Mesoporous silica nanoparticle nanocarriers: Biofunctionality and biocompatibility. Acc. Chem. Res.2013, 46, 792–801.
27. Pan, L. M.; He, Q. J.; Liu, J. N.; Chen, Y.; Ma, M.; Zhang, L. L.; Shi, J. L. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J. Am. Chem. Soc.2012, 134, 5722–5725.
28. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macro molecular therapeutics: A review. J. Control. Release2000, 65, 271–284.
29. Byrne, J. D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliver. Rev.2008, 60, 1615–1626.
30. Sun, C.; Lee, J. S. H.; Zhang, M. Q. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliver. Rev.2008, 60, 1252–1265.
31. Li, R. B.; Wu, R. A.; Zhao, L.; Hu, Z. Y.; Guo, S. J.; Pan, X. L.; Zou, H. F. Folate and iron difunctionalized multiwall carbon nanotubes as dual-targeted drug nanocarrier to cancer cells. Carbon2011, 49, 1797–1805.
32. Masters, J. R. Hela cells 50 years on: The good, the bad and the ugly. Nat. Rev. Cancer2002, 2, 315–319.
33. 4 nanocrystals with precise size control of one nanometre as potential MRI contrast agents. J. Mater. Chem.2011, 21, 2476–2481.
34. Kim, J.; Kim, H. S.; Lee, N.; Kim, T.; Kim, H.; Yu, T.; Song, I. C.; Moon, W. K.; Hyeon, T. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed.2008, 47, 8438–8441.
35. Slowing, I. I.; Trewyn, B. G.; Giri, S.; Lin, V. S.-Y. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv. Funct. Mater.2007, 17, 1225–1236.
36. Hakem, R.; Hakem, A.; Duncan, G. S.; Henderson, J. T.; Woo, M.; Soengas, M. S.; Elia, A.; de la Pompa, J. L.; Kagi, D.; Khoo, W. et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell1998, 94, 339–352.
37. Sudimack, J.; Lee, R. J. Targeted drug delivery via the folate receptor. Adv. Drug Deliver. Rev.2000, 41, 147–162.
38. Veiseh, O.; Gunn, J. W.; Zhang, M. Q. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliver. Rev.2010, 62, 284–304.
39. 4-loaded polymeric micelles for dual targeting of cancer cells. Polymer2008, 49, 3477–3485.